Bank of New York Mellon’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.87M | Buy |
488,441
+62,156
| +15% | +$397K | ﹤0.01% | 2589 |
|
|
2026
Q1 | $2.47M | Sell |
426,285
-7,977
| -2% | -$52.9K | ﹤0.01% | 2704 |
|
|
2025
Q4 | $3.41M | Sell |
434,262
-5,576
| -1% | -$43.9K | ﹤0.01% | 2535 |
|
|
2025
Q3 | $3.58M | Buy |
439,838
+62,711
| +17% | +$417K | ﹤0.01% | 2511 |
|
|
2025
Q2 | $1.76M | Buy |
377,127
+16,803
| +5% | +$77K | ﹤0.01% | 2812 |
|
|
2025
Q1 | $1.98M | Buy |
360,324
+37,949
| +12% | +$153K | ﹤0.01% | 2694 |
|
|
2024
Q4 | $1.09M | Sell |
322,375
-6,873
| -2% | -$22.1K | ﹤0.01% | 3104 |
|
|
2024
Q3 | $938K | Sell |
329,248
-99,306
| -23% | -$255K | ﹤0.01% | 3174 |
|
|
2024
Q2 | $964K | Buy |
428,554
+80,015
| +23% | +$161K | ﹤0.01% | 3225 |
|
|
2024
Q1 | $770K | Sell |
348,539
-21,903
| -6% | -$56.7K | ﹤0.01% | 3291 |
|
|
2023
Q4 | $871K | Sell |
370,442
-42,501
| -10% | -$78.4K | ﹤0.01% | 3264 |
|
|
2023
Q3 | $768K | Sell |
412,943
-11,411
| -3% | -$26.1K | ﹤0.01% | 3321 |
|
|
2023
Q2 | $1.11M | Buy |
424,354
+13,160
| +3% | +$33.5K | ﹤0.01% | 3136 |
|
|
2023
Q1 | $670K | Buy |
411,194
+388
| +0.1% | +$486 | ﹤0.01% | 3334 |
|
|
2022
Q4 | $546K | Sell |
410,806
-307
| -0.1% | -$433 | ﹤0.01% | 3497 |
|
|
2022
Q3 | $642K | Buy |
411,113
+35,112
| +9% | +$58.1K | ﹤0.01% | 3446 |
|
|
2022
Q2 | $579K | Buy |
376,001
+280,131
| +292% | +$591K | ﹤0.01% | 3501 |
|
|
2022
Q1 | $245K | Hold |
95,870
| – | – | ﹤0.01% | 4133 |
|
|
2021
Q4 | $281K | Buy |
95,870
+40,725
| +74% | +$88K | ﹤0.01% | 4127 |
|
|
2021
Q3 | $135K | Buy |
55,145
+11,534
| +26% | +$33.5K | ﹤0.01% | 4276 |
|
|
2021
Q2 | $177K | Sell |
43,611
-122,231
| -74% | -$466K | ﹤0.01% | 4126 |
|
|
2021
Q1 | $747K | Sell |
165,842
-311
| -0.2% | -$1.68K | ﹤0.01% | 3487 |
|
|
2020
Q4 | $818K | Buy |
166,153
+50,806
| +44% | +$254K | ﹤0.01% | 3362 |
|
|
2020
Q3 | $684K | Buy |
115,347
+12,513
| +12% | +$50K | ﹤0.01% | 3331 |
|
|
2020
Q2 | $273K | Buy |
102,834
+2,858
| +3% | +$9.95K | ﹤0.01% | 3717 |
|
|
2020
Q1 | $195K | Buy |
99,976
+16,624
| +20% | +$71.5K | ﹤0.01% | 3745 |
|
|
2019
Q4 | $588K | Buy |
83,352
+6,648
| +9% | +$54.9K | ﹤0.01% | 3510 |
|
|
2019
Q3 | $754K | Sell |
76,704
-228,070
| -75% | -$2.56M | ﹤0.01% | 3324 |
|
|
2019
Q2 | $3.49M | Buy |
304,774
+9,491
| +3% | +$99.6K | ﹤0.01% | 2505 |
|
|
2019
Q1 | $2.96M | Buy |
295,283
+275,342
| +1,381% | +$3.53M | ﹤0.01% | 2580 |
|
|
2018
Q4 | $339K | Buy |
19,941
+5,027
| +34% | +$101K | ﹤0.01% | 3665 |
|
|
2018
Q3 | $262K | Buy |
+14,914
| New | +$324K | ﹤0.01% | 3862 |
|
Other funds holding XERS
N
YIH
RHJA
Bank of New York Mellon's XERS Position: Q2 2026 in Review
Bank of New York Mellon increased its Xeris Biopharma Holdings (XERS) stake by 15% in Q2 2026, buying an estimated $397K and bringing the position to 488,441 shares worth $3.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2589.
Bank of New York Mellon first reported a position in XERS in Q3 2018 and has held it in 32 quarters since. 93 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- Bank of New York Mellon held 488,441 shares of Xeris Biopharma Holdings worth $3.87M as of Q2 2026.
- Bank of New York Mellon bought 62,156 Xeris Biopharma Holdings shares in Q2 2026, an estimated $397K.
- Xeris Biopharma Holdings made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2589 holding.
- Bank of New York Mellon first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 32 quarters since.
- 93 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.